Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased

16.7.2025 09:15:00 CEST | Business Wire | Press release

Share

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life.

Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health.

The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein.

This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily intake of spermidine. Spermidine is associated with benefits to longevity, cardiovascular health and brain health.

The paper states that “during (Almased’s) proteolytic enzyme procedure, bioactive and biogenic peptides, which were not detectable before in the raw materials, naturally occur. It can be assumed that the production process is significant in producing bioactive compounds responsible for unexpected positive effects on the metabolism, even in people who are not overweight”.

Other key findings in the 2022 review in Heliyon have shown:

  • 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine) compared to consuming a standard American diet containing the same amount of calories by the same individuals (Oliveira et al. 2022)
  • Almased group lost 145% more weight than the control group (-13lbs vs. -5.3lbs) in 12 weeks. Fat loss was 181% more in the Almased group (-9.9 lbs) than in the control group (-3.52 lbs) over the same period of time despite comparable weights before the study (Röhling et al. 2020)
  • Almased plus resistance training increased muscle strength by 33% versus resistance training alone (Deibert et al 2010)
  • Waist circumference reduction 239% greater in the Almased group compared to a fat-reduced diet (2.4in vs. 0.7in) after 6 weeks. Fat mass loss was 82% greater in the Almased group compared to a fat-reduced diet (11.2lbs vs. 6.1lbs) after 6 weeks (König et al 2008)
  • A study on post-menopausal women saw a 62% reduction in the prevalence of metabolic syndrome and significant fat loss without losing lean mass (Deibert et al. 2007)
  • Almased reduced liver fat content by an average of 56% and supports a healthy inflammatory response (Deibert et al 2019)
  • Almased preserved 100% muscle mass while losing weight (Deibert et al 2004)

Researchers found that Almased improves the fat burning process so you burn fat and calories more effectively (Oliveira et al 2021). In overweight and obese individuals, Almased meal replacement regimens resulted in greater reductions in body weight, body mass index (BMI), and fat mass compared to traditional low-calorie diets, while also improving glycemic control and lipid profiles.

Beyond weight management, the review highlights Almased’s role in supporting healthy blood sugar levels in both prediabetic and type 2 diabetic individuals. This indicates Almased is safe for people with diabetes.

The review also notes Almased’s unique anti-aging and wellness benefits. Regular use has been linked to healthy cell function, reduced stress markers, and better overall energy and mood. Almased’s protein-rich formula, containing essential amino acids and bioactive peptides, supports muscle preservation, cellular health, and supports a healthy inflammatory response, contributing to improved quality of life and longevity.

“The results presented underscore the efficacy of the soy-yogurt-honey formula (Almased) in weight management and the improvement of obesity-associated cardiovascular disease and metabolic risk factors.” said the study’s authors.

About Almased

Founded over 30 years ago in Germany by holistic therapist Hubertus Trouillé, and his son Andre Trouillé, Almased is a family-owned and operated company dedicated to promoting health and wellness worldwide. Recognized as Europe’s #1 science backed weight-loss meal replacement shake brand, Almased combines natural ingredients with a patented fermentation process to deliver high-quality, effective nutrition. With over 30 peer reviewed studies across 3 decades, Almased is a global leader in metabolic health. With a commitment to sourcing the highest quality ingredients in the world, Almased continues its mission to help people achieve healthier, happier lives with clean, sustainable products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250716374177/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lattice to Showcase Industry-Leading FPGA Innovations at FPGA Conference Europe 202616.6.2026 22:00:00 CEST | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA Conference Europe. Lattice will participate in various speaker sessions to showcase how low power FPGAs are driving innovation across multiple sectors. The company will also demonstrate its latest FPGA technology advancements in physical AI, advanced connectivity, security, and more. Who: Lattice Semiconductor What / When (GMT+2): June 30 – July 2: Lattice Presentations & Demo Showcase Speaker sessions: Day 1 – 3 Speaker Sessions: Lattice FPGA deep dive sessions spanning physical AI, advanced connectivity, security, and design tools Date Time Session June 30 9:45 a.m. FPGA Verification and Testing by Arrow 11:15 a.m. Trusted Resilience Edge: Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act 12 p.m. SIPHashIP for Embedded Security: Enabling RED Compliance and CRA Readiness in Smart AR/VR Systems 2:15 p.m. Foundations of FPGA Security

IQM Deploys Its First U.S. Quantum Computer at Oak Ridge National Laboratory16.6.2026 20:53:00 CEST | Press release

Pathfinder, a 20-qubit IQM Radiance system, is now operational at the home of Frontier, the world's most powerful supercomputer for open science. It’s ORNL's first commercially procured quantum computer and IQM's first system on U.S. soil. It will be connected to high-performance computing systems in the National Center for Computational Sciences Technology Integration Group's test bed. ORNL owns and operates the system on its own campus. IQM's deployment model gives customers direct ownership and control of their quantum infrastructure, including the IP. IQM has sold 23 full-stack quantum systems worldwide, more on-premises systems than any other manufacturer. The deployment expands IQM's commercial presence in the United States ahead of its planned Nasdaq listing through its merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). The Department of Energy's Oak Ridge National Laboratory (ORNL) today launched Pathfinder, the first commercially procured quantum computer at ORNL, built

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 19:00:00 CEST | Press release

Court orders Siemens to halt production and recall and destroy products across Germany, France and the Netherlands Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1

RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 18:30:00 CEST | Press release

Wavecrest Growth Partners invests to enable combination and support growth of the combined company RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, d

Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 17:42:00 CEST | Press release

Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye